pioglitazone hcl

Featured Products

Customer reviews
Product Description
A simple, precise, rapid, and reproducible reversed-phase high-performance liquid chromatography method is developed for the simultaneous estimation of metformin hydrochloride (MET), pioglitazone hydrochloride (PIO), and glimepiride (GLP) present in multicomponent dosage forms. Chromatography is carried out isocratically at 25 degrees C 0.5 degrees C on an Inertsil-ODS-3 (C-18) Column (250 x 4.60 mm, 5 microm) with a mobile phase composed of methanol-phosphate buffer (pH 4.3) in the ratio of 75:25 v/v at a flow rate of 1 mL/min. Detection is carried out using a UV-PDA detector at 258 nm. Parameters such as linearity, precision, accuracy, recovery, specificity, and ruggedness are studied as reported in the International Conference on Harmonization guidelines. The retention times for MET, PIO, and GLP are 2.66 + 0.5 min, 7.12 + 0.5 min, and 10.17 + 0.5 min, respectively. The linearity range and percentage recoveries for MET, PIO, and GLP are 10-5000, 10-150, and 1-10 microg/mL and 100.4%, 100.06%, and 100.2%, respectively. The correlation coefficients for all components are close to 1.
Product Description
In this book stable nanoparticles of pioglitazone HCL were prepared using biodegradable polymer, to increases bioavailability and to control release of drug. PGZ is used for the treatment of diabetes mellitus type 2. The drug modulates the transcription of the insulin-sensitive genes involved in the control of glucose and lipid metabolism in the muscular tissues and in the liver. It is an activator of the intracellular peroxisome proliferator-activated receptor-γ, and decreases metabolic and vascular insulin resistance causing rise in HDL-cholesterol plasma in humans. However, the poor aqueous solubility of PGZ may cause low bio absorption and limited therapeutic efficacy. So, the aim of the present study was to prepare stable PGZ loaded polymeric nanoparticles, to enhance the solubility and improve the bioavailability of the drug.
  1. Sickly service: Deadly North Texas tornado believed to have settle b end up speeds up to 200 mph
    GRANBURY, Texas - Forecasters say the tornado that claimed six lives and destroyed dozens of homes in North Texas is believed to have had winds up to 200 mph. The Subject Weather Service said the preliminary cloudburst estimate for Wednesday night's tornado in ...
  2. "Astellas Pharma Inc. - Artefact Pipeline Review - 2013" is now available at Expeditious Market Research
    15.05.2013 11:42:28 - Abstention Market Research recommends "Astellas Pharma Inc. - Work Pipeline Review - 2013" from Global Markets Straightforward, now available (live-PR.com) - Global Store Direct's pharmaceuticals report, "Astellas Pharma Inc. - Offering Pipeline ...
  3. Ranbaxy's proliferation in trouble with quality issues in global markets; new launches to be wonky curry favour with critical role
    Ranbaxy Laboratories, a chief Indian pharmaceutical company now controlled by Daiichi Sankyo Co. of Japan with shareholding of 63.52 per cent, has failed to inspire any investors confidence owing to poor pecuniary show in the first quarter ended March ...

FDA Approves ACTOplus met® XR (pioglitazone HCl and metformin ...

ACTOplus met XR combines ACTOS and metformin, two largely used medications in a single tablet. ACTOS instantly targets insulin resistance, a condition in which the fullness does not efficiently use the insulin it produces. (pioglitazone HCl) and metformin or who have not up to glycemic control on ACTOS or metformin solo.
Source: http://www.takeda.com/news/2009/20090514_3693.html

Google news feed

  1. pharmabiz.com Ranbaxy's progress in trouble with quality issues in global markets; new ...
    It launched desvenlafaxine, an NDA for Pristiq and gained retail share in Absorica, isotretenoin NDA, under a licensing concordat with Cipher Pharmaceuticals, Inc. The exclusivity period for pioglitazone hydrochloride authorised generic came to an end
  2. Men with bladder cancer sue drugmaker
    Their attorney, Todd Miller, said Actos, or pioglitazone hydrochloride, is a treatment for Type 2 diabetes and is the most prescribed medication for that category of diabetes, with $3.4 billion in sales in 2009. The lawsuit stated the European Cure-all
  3. Upcoming Catalysts Could Dragoon ChemoCentryx To Double In 2013
    Patients were randomized to earn a placebo, 5mg CCX140, 10mg CCX140, or 30mg pioglitazone hydrochloride then daily for four weeks. While the low dose CCX140 resulted in hemoglobin A1c changes be like to the placebo and pioglitazone groups
  4. Business Standard Ranbaxy Lab drops as secure effect pulls Q1 net profit lower
    The exclusivity patch for Pioglitazone hydrochloride authorised generic (AG) came to an end in mid February 2013, Ranbaxy Laboratories said in a assertion. During the quarter, the company has filed 3 abbreviated new pharmaceutical applications (ANDA) for the US
  5. Takeda Responds to Verdict in Diabetes Medicine Case
    The attendance is confident in the therapeutic benefits of ACTOS (pioglitazone HCl) and its esteem as a treatment for type 2 diabetes. "Philosophical safety is a critical priority for Takeda," said Greisman. "We intend to vigorously defend the company against
Actos (Pioglitazone HCL) - 4nrx
Actos (Pioglitazone HCL) - 4nrx
Actos (Pioglitazone HCL) - 4nrx
Actos (Pioglitazone HCL) - 4nrx
Pioglitazone Hydrochloride
Pioglitazone Hydrochloride
Pizaccord (Pioglitazone HCL) - 4nrx
Pizaccord (Pioglitazone HCL) - 4nrx